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Primary ciliary dyskinesia: keep it on 
your radar
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Primary ciliary dyskinesia (PCD) is a rare 
disorder of mucociliary clearance resulting 
in chronic oto-sinopulmonary disease. 
While the prevalence worldwide is esti-
mated to be 1:10 000–1:15 000, it may be 
much higher in certain communities, espe-
cially where consanguinity is more preva-
lent. In the British South Asian community, 
for example, the prevalence has been esti-
mated at 1:2450, similar to that of cystic 
fibrosis among caucasians.1 
In Thorax, Shoemark and colleagues2 
describe PCD in a highly consanguin-
eous UK South Asian community, due 
to homozygous missense variants in 
CCDC103, usually resulting in the loss 
of both outer and inner dynein arms. 
The investigators identified 86 patients of 
South Asian (primarily Pakistani) descent 
with clinical signs and symptoms of PCD 
from the UK National PCD Diagnostic 
and Management Services. These indi-
viduals had a compatible clinical pheno-
type, but diagnosis was complicated by 
the fact that many of the standard diag-
nostic tests for PCD had yielded variable 
and frequently normal results, including 
nasal nitric oxide, ciliary beat frequency 
and ciliary ultrastructure by transmission 
electron microscopy. Ultimately, next-gen-
eration sequencing confirmed a homozy-
gous pathogenic variant, p.His154Pro, in 
CCDC103 in 16 (19%) of these 86 cases, 
from 12 independent families.
From a clinical perspective, this report 
by Shoemark and colleagues2 highlights 
two important issues in the diagnosis 
of PCD. The first is that the preva-
lence of PCD may be higher than previ-
ously appreciated in certain populations, 
particularly in highly consanguineous 
communities. Indeed, in this report, all 
16 patients with homozygous CCDC103 
p.His154Pro mutations were children of
consanguineous parents. While this UK 
South Asian PCD cohort was enriched for 
the CCDC103 p.His154Pro mutation, a 
number of other PCD-causing mutations 
were also present, including CCDC40, 
DNAAF1, HEATR2, LRRC6, ZMYND10 
and RSPH4A. A high prevalence of PCD 
with genetic heterogeneity has similarly 
been reported among the close-knit, 
socially isolated, highly consanguineous 
US Amish and Mennonite communities, 
due to a founder pathogenic variant in 
DNAH5 and HEATR2.3
In the current study, the allele frequency 
of p.His154Pro from the ethnically 
matched control cohort was 0.00195 
(six of 3084 alleles). In the gnomAD 
public database ( gnomad. broadinstitute. 
org/), composed of >277 000 alleles 
from diverse population cohorts, the 
allele frequency of this missense variant is 
reported as 0.00123 and all alleles were 
present in a heterozygous state. Interest-
ingly, on reviewing individual cohorts in 
gnomAD, the observed allele frequency 
among South Asians (0.0032) is approx-
imately double that of European cohort 
(0.0015). Although, these allele frequen-
cies are seemingly very rare, they are much 
higher compared with the allele frequen-
cies of loss-of-function pathogenic variants 
in the same gene. For example, the homo-
zygous pathogenic variant (c.383_384insG 
(p.Pro129Serfs*25)) in CCDC103 that is 
associated with PCD4 is not represented in 
gnomAD. It is also pertinent to mention 
that p.His145Pro is represented in almost 
all ethnicities and races (except East 
Asian) in gnomAD, raising a question as to 
whether it represents a common ‘founder’ 
effect or a mutation ‘hotspot?’ It may have 
been useful if the authors had presented 
the haplotype data extracted from their 
next-generation sequencing dataset in the 
cases with the homozygous p.His154Pro 
variants of South Asian heritage and 
compared it with the few cases they had 
of European origin harbouring the same 
variant in order to better understand the 
differences in prevalence.
The second clinical issue highlighted by 
this report is that PCD may be difficult 
to diagnose, requiring dogged pursuit of 
multiple diagnostic tests. It is well estab-
lished that, among persons with a high clin-
ical index of suspicion, no single test can 
reliably diagnose PCD. Nasal nitric oxide 
can be normal in certain genetic causes of 
PCD, including some patients with muta-
tions in RSPH1 in addition to CCDC103. 
Electron microscopy of ciliary ultrastruc-
ture can be normal or inconclusive in up 
to one-third of patients.5 Genetic testing, 
though improving, cannot currently 
identify biallelic disease-causing muta-
tions in up to a third of individuals diag-
nosed with PCD. The 16 patients with 
PCD harbouring homozygous CCDC103 
p.His154Pro variant all possessed classic
characteristics of PCD, including situs
inversus totalis in 15 (81%). Yet, seven
(43%) had a normal nasal nitric oxide on
at least one occasion, a test that in general
has a high sensitivity and specificity for
PCD among persons with a compatible
clinical phenotype.6 Similarly, nine (56%)
had either normal or inconclusive ciliary
ultrastructure by electron microscopy,
nine had normal ciliary beat frequency
and seven were reported to have a normal
ciliary beat pattern. Indeed, five of the 16
did not receive a definitive diagnosis until
their genotype was confirmed. This report
by Shoemark and colleagues,2 thus, high-
lights the importance of taking a careful
history in order to establish a compatible
clinical phenotype7 and then pursuing a
multimodal diagnostic approach.
Another interesting aspect of the report 
is that, unlike many of the PCD-causing 
mutations to date, the p.His154Pro 
mutation is not a clear loss-of-function 
mutation. In fact, the mutation behaves 
as a hypomorph, and the evidence from 
this and prior studies4 is that the mutant 
CCDC103 protein is translated and 
retains at least partial function. This obser-
vation is no doubt partially responsible for 
the variable, sometimes normal, results 
observed in the diagnostic testing. In the 
case of CCDC103, patients with patho-
genic loss-of function variants have been 
previously identified, and it is clear that 
the p.His154Pro variant is pathogenic. 
However, as more genetic studies are 
completed and more missense variants are 
identified in potential PCD-causing genes, 
it will become increasingly important to 
determine if the variant is pathogenic. 
That is why it is important to note that 
the authors performed an experiment 
attempting to determine the functional 
consequence of the p.His154Pro mutation 
in the human protein. Again, the authors 
benefited from prior studies, notably 
those of King and Patel-King,8 who char-
acterised the CCDC103 protein from 
Chlamydomonas and showed the protein 
forms dimers and higher-order oligomers 
that bind microtubules with a periodicity 
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of 12 nm, potentially helping to define 
the sites of outer dynein arm binding. In 
this report, a gel-filtration experiment 
was performed to compare the wild-type 
CCDC103 with the pHis154Pro mutant 
protein. Although the proteins were 
assayed at very different concentrations 
(which is critical because oligomerisation 
is concentration dependent), the authors 
report a difference between the wild type 
and the mutant proteins, and the authors 
should be commended for going beyond 
characterising the genetics. There is a 
profound need for additional biochemical 
studies of this type, not only to determine 
if a particular missense variant is patho-
genic but also to begin to design targeted 
therapies for treatment. The development 
of lumacaftor to stabilise the common 
F508del mutation in cystic fibrosis is a clear 
example of how understanding the basic 
biochemical defect can lead to improved 
treatment. The use of model systems (eg, 
Chlamydomonas, Xenopus, zebrafish) 
and/or human cell cultures to define the 
functional consequences of missense vari-
ants, like the p.His154Pro in CCDC103, 
will be of increasing importance as the 
development of personalised therapies for 
patients with PCD accelerates.
Advances in next-generation sequencing 
technologies have profoundly increased 
our understanding of human genetic 
disorders. However, these advances 
have also led to the identification of an 
enormous number of variants of uncer-
tain significance (VUS), interpretation of 
which remains challenging. The Amer-
ican College of Medical Genetics and 
Genomics, together with the Association 
for Molecular Pathology, has published 
recommendations for the interpretation 
of these variants,9 and functional studies 
such as those performed by Shoemark 
and colleagues2 are considered a powerful 
tool in support of pathogenicity. The 
genetic diagnosis of PCD is especially 
challenging, as mutations in 39 genes 
have been implicated and this number 
continues to grow.10–15 The majority of 
the published literature describes PCD 
cases with two loss-of-function (trun-
cating and splice site) pathogenic vari-
ants, raising the question of missing 
genetic diagnoses due to the interpretive 
limitations of missense, in-frame and 
close to the splice-site intronic variants. 
These latter variants also pose a dilemma 
for reporting of genetic results in the clin-
ical setting. Various strategies including 
computational prediction algorithms may 
aid with interpretation, but often provide 
conflicting information. Functional 
studies such as described in this manu-
script are a step in the right direction but 
are cost, time and labour intensive. The 
extensive genetic heterogeneity of PCD 
(and other Mendelian disorders) will 
continue to generate numerous VUSs. 
One possible way forward in elucidating 
their pathogenicity is to develop high 
throughput disease-specific functional 
assays, such as the recently described 
multiplexed assay for variant effect.16
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